Adaptive Biotechnologies Stock Options
| ADPT Stock | USD 6.81 0.11 1.59% |
Adaptive Biotechnologies' latest option contracts expiring on April 17th 2025 are carrying combined implied volatility of 2.12 with a put-to-call open interest ratio of 0.27 over 10 outstanding agreements suggesting investors are buying way more calls than puts on contracts expiring on April 17th 2025.
Open Interest Against April 17th 2025 Option Contracts
Adaptive Biotechnologies option prices can potentially be used to forecast stock returns because most option chains provide information not only about the current prices but also about the future conditions in Adaptive Biotechnologies' lending market. For example, when Adaptive Biotechnologies' puts are not actively trading or completely missing in the marketplace, investors can use it to internalize expected shorting costs. So if an investor is writing a put option on Adaptive Biotechnologies, he or she must hedge the risk by shorting Adaptive Biotechnologies stock over its option's life.
2025-04-17
The chart above shows Adaptive Biotechnologies' distribution of open interest by maturity on contracts that have not yet been settled. The area between the two highest points is the projection of the price at expiration. Adaptive Biotechnologies' open interest chart also provides vital information regarding the liquidity of an option. If there is no open interest for Adaptive Biotechnologies' option, there is no secondary market available for investors to trade.
In The Money vs. Out of Money Option Contracts on Adaptive Biotechnologies
Analyzing Adaptive Biotechnologies' in-the-money options over time can help investors to take a profitable long position in Adaptive Biotechnologies regardless of its overall volatility. This is especially true when Adaptive Biotechnologies' options are deep in the money. These options can be identified using deltas that are over 0.75. Deep in-the-money Adaptive Biotechnologies' options could be used as guardians of the underlying stock as they move almost dollar for dollar with Adaptive Biotechnologies' stock while costing only a fraction of its price.
Adaptive Biotechnologies In The Money Call Balance
When Adaptive Biotechnologies' strike price is surpassing the current stock price, the option contract against Adaptive Biotechnologies Corp stock is said to be in the money. When it comes to buying Adaptive Biotechnologies' options that are 'In the Money' or 'Out of the Money', the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
While 'out-of-the-money' option contracts written on Adaptive Biotechnologies Corp are typically viewed as the more aggressive, there are potential upsides to purchasing these types of options contracts. For one, the cost to buy an 'Out of the Money' option is lower than the cost to buy an 'In the Money' option. This cost-benefit is due to the fact that at the time of the purchase, 'Out of the Money' contracts have no intrinsic value. So, while the potential for a 100% loss is more significant, the cost and risk to enter the trade are lower.
Adaptive Current Options Market Mood
Adaptive Biotechnologies' open interest and total value indicators provide investors with the necessary information to digest the overall options buildup for its expiring contracts. In addition, it helps Adaptive Stock's traders understand whether a recent fall or rise in the market is unreasonable and if the time has come to take contrarian positions. These ratios are calculated based on options trading volumes and current open interest.
Put-to-Call Open Interest
Put-to-Call Volume
Most options investors, including buyers and sellers of Adaptive Biotechnologies' calls and puts, are not very successful. It is estimated that an average options trader loses somewhere between 80% to 90% of the time. Adaptive Biotechnologies' option open interest and volume spread between outstanding puts and calls are regarded by many investors as reliable indicators of the overall future market direction.
Rule 16 of the current Adaptive contract
Base on the Rule 16, the options market is currently suggesting that Adaptive Biotechnologies Corp will have an average daily up or down price movement of about 0.13% per day over the life of the 2025-04-17 option contract. With Adaptive Biotechnologies trading at USD 6.81, that is roughly USD 0.009023. If you think that the market is fully incorporating Adaptive Biotechnologies' daily price movement you should consider buying Adaptive Biotechnologies Corp options at the current volatility level of 2.12%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
Adaptive |
Purchasing Adaptive Biotechnologies options can give investors a meaningful hedge against losses and, therefore, could be used conservatively to decrease the volatility of your portfolio. However, many options could also amount to little more than gambling, significantly enhancing your overall portfolio risk. One simple example of these aggressive strategies is the sale of "uncovered" Adaptive calls. Remember, the seller must deliver Adaptive Biotechnologies Corp stock to the call owner when a call is exercised.
Adaptive Biotechnologies Option Chain
When Adaptive Biotechnologies' strike price is surpassing the current stock price, the option contract against Adaptive Biotechnologies Corp stock is said to be in the money. When it comes to buying options that are ITM or OTM, the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
Adaptive Biotechnologies' option chain is a display of a range of information that helps investors for ways to trade options on Adaptive. In general, an option chain provides a helpful tool for investors to see all available option contracts, both puts, and calls, for Adaptive. It also shows strike prices and maturity days for a Adaptive Biotechnologies against a given expiration period. The table below combines all the option information in the form of a chain but before you use it, remember that it entails significant risk and it is not for everyone. | Open Int | Strike Price | Current Spread | Last Price | |||
Call | ADPT250417C00002500 | 6 | 2.5 | 2.0 - 4.9 | 3.36 | In |
Call | ADPT250417C00005000 | 54 | 5.0 | 0.75 - 3.4 | 2.25 | In |
Call | ADPT250417C00007500 | 137 | 7.5 | 0.25 - 5.0 | 1.25 | Out |
Call | ADPT250417C00010000 | 46 | 10.0 | 0.0 - 0.9 | 0.4 | Out |
Call | ADPT250417C00012500 | 1 | 12.5 | 0.0 - 4.3 | 0.01 | Out |
Put | ADPT250417P00002500 | 10 | 2.5 | 0.0 - 4.1 | 0.6 | Out |
Put | ADPT250417P00005000 | 55 | 5.0 | 0.0 - 1.05 | 0.4 | Out |
Put | ADPT250417P00007500 | 1 | 7.5 | 0.0 - 5.0 | 3.25 | In |
Put | ADPT250417P00010000 | 0 | 10.0 | 1.0 - 5.1 | 1.0 | In |
Put | ADPT250417P00012500 | 1 | 12.5 | 3.5 - 8.0 | 6.6 | In |
Adaptive Biotechnologies Selling And Marketing Expenses Over Time
Selling And Marketing Expenses |
| Timeline |
Adaptive Biotechnologies Market Cap Over Time
Market Cap |
| Timeline |
Adaptive Total Stockholder Equity
Total Stockholder Equity |
|
Adaptive Biotechnologies Corporate Management
| Stacy JD | General VP | Profile | |
| Stacy Taylor | General VP | Profile | |
| Yi Zhou | Chief Officer | Profile | |
| Tycho Peterson | Chief Officer | Profile | |
| Kyle Piskel | Principal Officer | Profile | |
| Susan Bobulsky | Chief MRD | Profile |
Additional Tools for Adaptive Stock Analysis
When running Adaptive Biotechnologies' price analysis, check to measure Adaptive Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptive Biotechnologies is operating at the current time. Most of Adaptive Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Adaptive Biotechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptive Biotechnologies' price. Additionally, you may evaluate how the addition of Adaptive Biotechnologies to your portfolios can decrease your overall portfolio volatility.